Documents
Improved Fragment Separation using bioZen™ 1.8 μm SEC-3 (TN-1246)
Monoclonal antibody (mAb) aggregates are often found at very low levels (<0.1 % by peak area compared to monomer) and to address this need for low level detection a robust set of bioZen SEC columns were developed which combine UHPLC efficiency and high sensitivity to drive resolution and identification of even lower level targets. Alongside this mAb fragment separation is often required adequate resolution, thus peak shape has become even more crucial to the successful outcome of the method. In this technote we evaluate the benefits of the bioZen 1.8 μm SEC-3 column packed into BioTi™ hardware and compare it with a traditional size exclusion column to compare the efficiency, resolution and reproducibility of the two columns.
Improved Fragment Separation using bioZen™ 1.8 μm SEC-3 (TN-1246)
Monoclonal antibody (mAb) aggregates are often found at very low levels (<0.1 % by peak area compared to monomer) and to address this need for low level detection a robust set of bioZen SEC columns were developed which combine UHPLC efficiency and high sensitivity to drive resolution and identification of even lower level targets. Alongside this mAb fragment separation is often required adequate resolution, thus peak shape has become even more crucial to the successful outcome of the method. In this technote we evaluate the benefits of the bioZen 1.8 μm SEC-3 column packed into BioTi™ hardware and compare it with a traditional size exclusion column to compare the efficiency, resolution and reproducibility of the two columns.
Document Type:
Technical Notes
Techniques:
Brands:
Separation Modes:
Size Exclusion
Phases: